Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer

被引：0
|
作者：
Liu, Yuhan [1 ]
Zou, Yuhan [1 ]
Ye, Yangli [2 ]
Chen, Yong [3 ]
机构：
[1] Shandong Second Med Univ, Sch Clin Med, Weifang, Peoples R China
[2] Shandong Second Med Univ, Coll Life Sci & Technol, Weifang, Peoples R China
[3] Shandong Second Med Univ, Key Lab Immune Microenvironm & Inflammatory Dis Re, Sch Basic Med Sci, Weifang, Peoples R China
来源：
CANCER MEDICINE | 2024年 / 13卷 / 22期
关键词：
classification; drug resistance; genomic alterations; signaling pathways; triple-negative breast cancer; HEDGEHOG SIGNALING PATHWAY; PEMBROLIZUMAB PLUS CHEMOTHERAPY; CISPLATIN RESISTANCE; STEM-CELLS; PACLITAXEL RESISTANCE; MUTATIONAL PROCESSES; THERAPEUTIC TARGET; PROMOTES; TRANSCRIPTION; MDA-MB-231;
D O I：
10.1002/cam4.70410
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BackgroundTriple-negative breast cancer (TNBC) is a heterogeneous disease characterized by high aggressiveness, high malignancy, and poor prognosis compared to other breast cancer subtypes.ObjectiveThis review aims to explore recent advances in understanding TNBC and to provide new insights and potential references for clinical treatment.MethodsWe examined current literature on TNBC to analyze molecular subtypes, genetic mutations, signaling pathways, mechanisms of drug resistance, and emerging therapies.ResultsFindings highlight key aspects of TNBC's molecular subtypes, relevant mutations, and pathways, alongside emerging treatments that target drug resistance mechanisms.ConclusionThese insights into TNBC pathogenesis may help guide future therapeutic strategies and improve clinical outcomes for patients with TNBC.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Advances in Understanding Mitochondrial MicroRNAs (mitomiRs) on the Pathogenesis of Triple-Negative Breast Cancer (TNBC)
    Lin, Hung-Yu
    Chu, Pei-Yi
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
  • [2] Pathogenesis of Triple-Negative Breast Cancer
    Derakhshan, Fatemeh
    Reis-Filho, Jorge S.
    ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2022, 17 : 181 - 204
  • [3] Advances in immunotherapy for triple-negative breast cancer
    Yang Liu
    Yueting Hu
    Jinqi Xue
    Jingying Li
    Jiang Yi
    Jiawen Bu
    Zhenyong Zhang
    Peng Qiu
    Xi Gu
    Molecular Cancer, 22
  • [4] Understanding and Treating Triple-Negative Breast Cancer
    Anders, Carey
    ONCOLOGY-NEW YORK, 2008, 22 (11): : 1233 - 1239
  • [5] Understanding the biology of triple-negative breast cancer
    Criscitiello, C.
    Azim, H. A., Jr.
    Schouten, P. C.
    Linn, S. C.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 13 - 18
  • [6] Advances in the Treatment of Triple-negative Early Breast Cancer
    Basso, Stefano M. M.
    Santeufemia, Davide A.
    Fadda, Giovanni M.
    Tozzoli, Renato
    D'Aurizio, Federica
    Lumachi, Franco
    MEDICINAL CHEMISTRY, 2016, 12 (03) : 268 - 272
  • [7] Advances in Targeted Therapies for Triple-Negative Breast Cancer
    McCann, Kelly E.
    Hurvitz, Sara A.
    McAndrew, Nicholas
    DRUGS, 2019, 79 (11) : 1217 - 1230
  • [8] Recent advances in the treatment of triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Kunkiel, Michal
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (06): : 433 - 443
  • [9] Advances in Targeted Therapies for Triple-Negative Breast Cancer
    Kelly E. McCann
    Sara A. Hurvitz
    Nicholas McAndrew
    Drugs, 2019, 79 : 1217 - 1230
  • [10] Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
    Mahtani, Reshma
    Kittaneh, Muaiad
    Kalinsky, Kevin
    Mamounas, Eleftherios
    Badve, Sunil
    Vogel, Charles
    Lower, Elyse
    Schwartzberg, Lee
    Pegram, Mark
    CLINICAL BREAST CANCER, 2021, 21 (05) : 383 - 390
12345